ARTICLE | Product Development
Arrowhead siRNA data in obesity mark POC for adipose delivery
Biotech looks to raise $700M as its ALK7 data stand out and INHBE results track with peers
January 7, 2026 2:12 AM UTC
Interim obesity data from Arrowhead’s INHBE-targeting siRNA are largely in line with those of a competing therapy from Wave Life Sciences. But early results from ARO-ALK7, which targets ALK7, mark something potentially more important: the first clinical proof that Arrowhead can reliably silence genes in adipose tissue, extending RNAi beyond the liver.
The findings, announced Tuesday, give Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) a competitive footing in the obesity arena, with investors sending its shares up 11%, valuing the biotech at more than $9.5 billion. ...